Relevance of ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec to "Which measured methylation workflow detects tumour-derived plasma DNA and, where separately supported, identifies tissue of origin?"
- Use case
- Select a plasma ctDNA methylation detection workflow
- Assessed by
- CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- Relevance
- Proxy evidence
- Endpoint
- Sensitivity (95% CI, TP/total) at 98% specificity under 10-fold cross-validation on 833 cancers and 560 non-cancers for the whole-genome methylation classifier and the five other classifiers that were analysed double-blinded in validation
Measures the use case's endpoint, all-stage cancer detection sensitivity at a declared specificity on plasma cfDNA, for a whole-genome bisulfite methylation classifier, alongside mutation, copy-number, fragment and clinical classifiers run on the same blood draws.
6 reviewed evaluations
- clinical data on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- SCNA on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- SCNA-WBC on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- SNV on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- SNV-WBC on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
- WG methylation on CCGA substudy 1 training set: cancer signal sensitivity at 98% specificity under 10-fold cross-validation
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
21 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Citation locations1 values
| Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Comparison group jamshidi2022-ccga1-detection Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Comparison title CCGA substudy 1: cfDNA classifiers on the same participants at a post hoc 98% specificity Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Constraints3 values
| Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Endpoint Sensitivity (95% CI, TP/total) at 98% specificity under 10-fold cross-validation on 833 cancers and 560 non-cancers for the whole-genome methylation classifier and the five other classifiers that were analysed double-blinded in validation Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Excluded evaluations3 values
| Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Claimed field links:assessed_by:ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
| Headline metric sensitivity-at-98-percent-specificity Context-only references | Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Limitations8 values
| Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Pinned records15 values
| Evaluation of cell-free DNA approaches for multi-cancer early detection ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods Version: Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: pdftotext -layout text layer, parsed by extract/extract_ctdna_jamshidi.py |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Evaluation of cell-free DNA approaches for multi-cancer early detection · Original source · Cancer Cell 40(12):1537-1549.e12, published 2022-12-12; publisher PDF (1-s2.0-S153561082200513X-main.pdf) as deposited by the Francis Crick Institute on figshare, 10.25418/crick.21731870.v1
Technical metadata and extraction receipts
Stable ID: use-case-mapping-ctdna-jamshidi-20261010-meth-training-cv
- field
- links:assessed_by:ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec
- value
- ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec
- relevance
- proxy
- endpoint
- Sensitivity (95% CI, TP/total) at 98% specificity under 10-fold cross-validation on 833 cancers and 560 non-cancers for the whole-genome methylation classifier and the five other classifiers that were analysed double-blinded in validation
- rationale
- Cross-validated sensitivity at a post hoc 98% specificity within the training set used to design the classifiers. Proxy, because the same study's independent validation set gives the direct estimate for the same locked classifiers; the training values show how much sensitivity fell between training and validation (WG methylation 39% to 34%). Developer-run and case-control. The CCGA samples are not public and do not overlap the cohorts of this use case's other judgements.
- constraints
- Inspect every linked evaluation's source locator and preserved limitations before citing a result.; Do not combine this mapping's evaluations with any other protocol's results; cohorts, assays and thresholds differ.; The 98% specificity threshold was set post hoc within each set and is not a locked screening threshold.
- limitations
- Developer study: GRAIL designed the assays and classifiers, ran every arm, and reports the comparison.; The 98% specificity threshold was set post hoc within each set, including the validation set, so it is not a threshold locked before validation.; Case-control enrolment of clinically diagnosed cancers and matched non-cancer participants, not an intended-use screening population.; Prototype assays; the targeted methylation test developed afterwards is a different assay and is not scored here.; The fragment endpoints, fragment lengths, allelic imbalance and pan-feature classifiers were developed after validation blinding was lifted; the other classifiers were blinded.; Table 3 scores 833 training and 464 validation cancers against 854 and 485 analysable cancers in Table 1. STAR Methods restrict detection to solid cancers, and Table 1 lists 11 plasma cell neoplasms and 10 leukaemias in training and 8 and 13 in validation, which is 21 in each set; lymphomas stay in.; Specificity was 97.9% (548/560) in training and 97.8% (354/362) in validation for every cfDNA classifier, slightly below the 98% target.; Only the six classifiers analysed double-blinded in validation are shown; the three developed after unblinding are excluded.
- citation locators
- source id: ctdnajam-20261010-source-jamshidi2022; locator: Table 3, training columns; STAR Methods
- source locator
- ctdnajam-20261010-source-jamshidi2022: Table 3, training columns; STAR Methods
- revision
- 1
- reason
- Add the CCGA substudy 1 same-sample comparison of cfDNA classifiers (Jamshidi et al. 2022), retrieved 2026-10-10.
- comparison group
- jamshidi2022-ccga1-detection
- comparison title
- CCGA substudy 1: cfDNA classifiers on the same participants at a post hoc 98% specificity
- headline metric
- sensitivity-at-98-percent-specificity
- stratum label
- Training set, 10-fold cross-validation
- stratum order
- 1
- excluded evaluations
- id: ctdnajam-20261010-eval-training-fragment-endpoints; reason: Developed after validation blinding was lifted (STAR Methods), so its design may reflect the unblinded validation results. Excluded from this judgement at independent review 2026-10-10; it stays in the fragmentomics judgements with that limitation.; id: ctdnajam-20261010-eval-training-fragment-lengths; reason: Developed after validation blinding was lifted (STAR Methods), so its design may reflect the unblinded validation results. Excluded from this judgement at independent review 2026-10-10; it stays in the fragmentomics judgements with that limitation.; id: ctdnajam-20261010-eval-training-allelic-imbalance; reason: Developed after validation blinding was lifted (STAR Methods), so its design may reflect the unblinded validation results. Excluded from this judgement at independent review 2026-10-10; it stays in the fragmentomics judgements with that limitation.
- reviewed evaluations
- ctdnajam-20261010-eval-training-clinical-data; ctdnajam-20261010-eval-training-scna; ctdnajam-20261010-eval-training-scna-wbc; ctdnajam-20261010-eval-training-snv; ctdnajam-20261010-eval-training-snv-wbc; ctdnajam-20261010-eval-training-wg-methylation
- review
- method: automated-source-review; reviewer: claude; reviewer note: Separate Claude review agent, independent of the extractor; no human review claimed; reviewed at: 2026-10-10T09:00:00Z; note: Independent review of endpoint fit, relevance grade, limitations, exclusions and grouping against the use case and the article; every value of the listed evaluations was checked against Table 3 or the Results text, with percentages and Clopper-Pearson intervals recomputed. Developer study; no execution, reproduction, human scientific review or clinical validation.
- pins
- record id: ctdnajam-20261010-eval-training-clinical-data; fields: status; links; attributes.origin; attributes.comparison; sha256: 1d52b51d39fa7581e10f3a7fc9011a7d0d58bbe4a0d40d22e728eeccb33136fb; record id: ctdnajam-20261010-eval-training-scna; fields: status; links; attributes.origin; attributes.comparison; sha256: 308b3a9f74982fbe8704819025d5434558cf07ab23b8b80e2c06d7ea9e36b864; record id: ctdnajam-20261010-eval-training-scna-wbc; fields: status; links; attributes.origin; attributes.comparison; sha256: d60a82250add685a70cec0035e890ff8cca597a2f18ee755711cda02d740da51; record id: ctdnajam-20261010-eval-training-snv; fields: status; links; attributes.origin; attributes.comparison; sha256: b192bf6cb8b40bfd6a9bac2d7e8e46dc3b8260dc3ba58443d7f4d4db21c5c9cc; record id: ctdnajam-20261010-eval-training-snv-wbc; fields: status; links; attributes.origin; attributes.comparison; sha256: 9eeb50a8399c1e7382a39110181b54c03a30f28899434225f6090baf61fd98ad; record id: ctdnajam-20261010-eval-training-wg-methylation; fields: status; links; attributes.origin; attributes.comparison; sha256: ee219db71a2d985de4b230b91d409083aa64e21e996808f8df1bf3297e6562a9; record id: ctdnajam-20261010-protocol-ccga1-training-cv-sens-98spec; fields: status; name; description; facets; source_ids; links; attributes; sha256: 989df2f01c0e0680982046687453cf8e01eaff06fdd2cef30b77956a4c047935; record id: ctdnajam-20261010-result-training-clinical-data-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 9aa5ea94d9bc7d5a2d13ca1fb78c40c6eb3ec8d957f7c10d44ef389c0dc3b25f; record id: ctdnajam-20261010-result-training-scna-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 55800b64e75e349c9574302a38d6f4e067437e0161e3e02c76d784e3bfc486a0; record id: ctdnajam-20261010-result-training-scna-wbc-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 473993745009b5df1d857d423f4dcb9e5c66f3f43e99ce6fb4397d3c6a81bebd; record id: ctdnajam-20261010-result-training-snv-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 9c699789969b9519eb9134425fbb111acd7b94729d7dd9e2f08ab2d306436716; record id: ctdnajam-20261010-result-training-snv-wbc-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 311545249c9bd2489f49e6fb53bf049a45a90e4987054e8f1088bb2cf8f7151e; record id: ctdnajam-20261010-result-training-wg-methylation-sensitivity; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 3d870e6f22ac02c7ff9605e5bd212bbd87657fc2e225ec789da75e4b2ddd3f40; record id: ctdnajam-20261010-source-jamshidi2022; fields: status; attributes.artifact_sha256; sha256: 49c49ed0c10c6121644dee3068618d9f5a06bbc63f5979bc8417acd9c1c0e56e; record id: use-case-plasma-ctdna-methylation; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 4d9542463e1400d5d9701c7f52859a23e4c78804cbda1477663445f945e22429